Comparison between sirolimus- and paclitaxel-eluting stents in complex patient and lesions subsets

Catheterization and Cardiovascular Interventions

Volumn 70, Issue 2, 2007, Pages 167-172

  Roy, Probal ^a   Torguson, Rebecca ^a   Okabe, Teruo ^a   Pinto Slottow, Tina L ^a   Steinberg, Daniel H ^a   Smith, Kimberly ^a   Xue, Zhenyi ^a   Gevorkian, Natalie ^a   Satler, Lowell L ^a   Kent, Kenneth M ^a   Suddath, William O ^a   Pichard, Augusto D ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Complex subsets; Paclitaxel eluting stents; Sirolimus eluting stents

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PACLITAXEL; RAPAMYCIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY STENT; DRUG ELUTING STENT; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CORONARY ANGIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; PROSTHESIS DESIGN; RESEARCH DESIGN; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SIROLIMUS; STENTS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34547622336     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21122     Document Type: Article

References (20)

1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
2. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
3. Marx SO, Marks AR. Bench to bedside: The development of rapamycin and its application to stent restenosis. Circulation 2001;104:852-855.
4. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995;332:1004-1014.
5. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HP. REALITY Trial Investigators. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: The REALITY trial: A randomized controlled trial. JAMA 2006;295:895-904.
6. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schomig A. ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-670.
7. Windecker S, Remondino A, Eberli FR, Juni P, Raber L, Wenaweser P, Togni M, Billinger M, Tuller D, Seiler C, Roffi M, Corti R, Sutsch G, Maier W, Luscher T, Hess OM, Egger M, Meier B. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005;353:653-662.
8. Kastrati A, Dibra A, Eberle S, Mehilli J, Suarez de Lezo J, Goy JJ, Ulm K, Schomig A. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: Meta-analysis of randomized trials artery disease: Meta-analysis of randomized trials. JAMA 2005;294:819-825.
9. Ong AT, Serruys PW, Aoki J, Hoye A, van Mieghem CA, Rodriguez-Granillo GA, Valgimigli M, Sonnenschein K, Regar E, van der Ent M, de Jaegere PP, McFadden EP, Sianos G, van der Giessen WJ, de Feyter PJ, van Domburg RT. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: One-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 2005;45:1135-1141.
10. Ong AT, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Valgimigli M, Tsuchida K, Sonnenschein K, Regar E, van der Giessen WJ, de Jaegere PP, Sianos G, McFadden EP, de Feyter PJ, van Domburg RT, Serruys PW. Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus-versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). Am J Cardiol 2005;96:358-362.
11. Kuchulakanti PK, Chu WW, Torguson R, Clavijo L, Wolfram R, Mishra S, Xue Z, Gevorkian N, Suddath WO, Satler LF, Kent KM, Pichard AD, Waksman R. Sirolimus-eluting stents versus Paclitaxel-eluting stents in the treatment of coronary artery disease in patients with diabetes mellitus. Am J Cardiol 2006;98:187-192.
12. Valgimigli M, Malagutti P, Aoki J, Garcia-Garcia HM, Rodriguez Granillo GA, van Mieghem CA, Ligthart JM, Ong AT, Sianos G, Regar E, Van Domburg RT, De Feyter P, de Jaegere P, Serruys PW. Sirolimus-eluting versus paclitaxel-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: A combined RESEARCH and T-SEARCH long term analysis. J Am Coll Cardiol 2006;47:507-514.
13. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schuhlen H, Schmitt C, Dirschinger J, Schomig A. ISAR-DESIRE Study Investigators Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: A randomized controlled trial. JAMA 2005;293:165-171.
14. Airoldi F, Briguori C, Iakovou I, Stankovic G, Biondi-Zoccai G, Carlino M, Chieffo A, Montorfano M, Cosgrave J, Michev I, Rogacka R, Sangiorgi GM, Colombo A. Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary instent restenosis. Am J Cardiol 2006;97:1182-1187.
15. Chu WW, Kuchulakanti PK, Wang B, Clavijo LC, Suddath WO, Pichard AD, Satler LF, Kent KM, Waksman R. Efficacy of sirolimus-eluting stents as compared to paclitaxel-eluting stents for saphenous vein graft intervention. J Interv Cardiol 2006;19:121-125.
16. Edelman ER, Rogers C. Stent-versus-stent equivalency trials: Are some stents more equal than others? Circulation 1999;100: 896-898.
17. Hausleiter J, Kastrati A, Mehilli J, Schuhlen H, Pache J, Dotzer F, Sattelberger U, Dirschinger J, Schomig A. Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: Results from the ISAR STEREO trial. Am Heart J 2003;146:882-886.
18. Windecker S, Remondino A, Eberli FR, Juni P, Raber L, Wenaweser P, Togni M, Billinger M, Tuller D, Seiler C, Roffi M, Corti R, Sutsch G, Maier W, Luscher T, Hess OM, Egger M, Meier B. Sirolimus-eluting and paclitaxel-eluting stents for coronary revasculaization. N Engl J Med 2005;353:653-662.
19. Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schomig A. Intracoronary Drug-Eluting Stenting to Abrogate Restenosis in Small Arteries (ISAR-SMART 3) Study Investigators. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 2006;27:260-266.
20. Camenzind E. Safety of drug eluting stents: A meta analysis of 1st Generation DES programs. Presented at European Society of Cardiology (ESC/WCC) Scientific Congress, September 2006.